Endologix (ELGX)

14.27 +0.19  +1.35%  May 25, 11:00PM Go Pro
Watch this stock
View Full Chart ELGX Price Chart

Key Stats

Market Cap 830.23M
Revenue Growth 32.19%
Profit Margin -68.12%
Earnings Yield -4.98%
Dividend Yield 0.00%
Earnings Per Share TTM -0.71
PE Ratio
Price / Sales Ratio 9.288
52 Week High 15.29
52 Week Low 7.25
Beta 1.138
View Pro Ratings Details

YCharts Pro Ratings

Go Pro.
Learn More
  • Pro Value Score Go Pro
  • Pro Fundamental Score Go Pro
  • Pro Valuation from Historical Multiples Go Pro

News

May 16 Endologix's CEO Presents at the 2012 Bank of America Merrill Lynch Health Care Confer...
May 10 ENDOLOGIX INC /DE/ Files SEC form 10-Q, Quarterly Report
May 09 Endologix to Present at the 2012 Bank of America Merrill Lynch Health Care Conference GlobeNewswire
May 07 EBR: Watchlist/worksheet/4 Trading Ideas: $DF $EQR $ENOC $AFFX $ELGX $OFC http://stks.co/3hIf by TheEquitiesRoom
May 06 PocketPullback watchlist for tmrw (3-5 day orderly pullback from strong trend/move): $DDD $DFT $PANL $ELGX $IR $ by TheEquitiesRoom
May 04 Is Endologix Going to Burn You? Fool
May 01 $ELGX Insider Sale: $2M of stock sold by Stefan Schreck on May 1, 2012 http://stks.co/3cAi by MarketBrief
Apr 26 Endologix's CEO Discusses Q1 2012 Results - Earnings Call Transcript Seeking Alpha
Apr 26 Listen to $ELGX Q1 2012 earnings call - live at 05:00 PM, ondemand after - http://stks.co/3XWb by earningscast
Apr 26 Endologix, Inc. (ELGX) Posts Q1 Loss of 7c/Share; Reaffirms Outlook Street Insider
Mar 19 Med. Instruments & Supplies industry grp seems 2 really want 2 push to new 52 highs $MR $AIS $BAX $ELGX $XRAY follow this grp by ajb_2010

Profile

Exchange: NASDAQGM       Sector: Healthcare       Industry: Medical Instruments & Supplies

Endologix, Inc. develops and manufactures minimally invasive treatments for aortic disorders. The Company's focus is endovascular stent grafts for the treatment of Abdominal Aortic Aneurysms (AAA). The firm currently marketing Powerlink Delivery System an innovative, one-piece endoluminal stent graft (ELG) used in treating AAA that has significant advantages when compared with marketed stent alternatives. The company was founded in March 1992 and is headquartered in Irvine, California.

1 Year Total Return Performance

This total returns chart shows the returns to an investor from both price appreciation and dividends (dividends are assumed to be reinvested). Endologix is up 69.48% over the last year vs S&P 500 Total Return up 1.18%, Strategic Diagnostics down 16.67%, and STAAR Surgical Company up 52.63%.

  • ELGX Total Returns
  • ^SPXTR Total Returns
  • SDIX Total Returns
  • STAA Total Returns

Fundamentals

Fundamental analysis of a business involves analyzing its financial statements and health, its management and competitive advantages. The key financial statements of a company are the income statement, balance sheet and cash flow statement.

Income Statement View Statement

Balance Sheet View Statement

Get Quote for

Pro Strategies Featuring ELGX

Did Endologix make it into our Pro Portfolio Strategies?

Start your YCharts Pro membership now to find out.

ELGX Charts

Recent Quotes

Symbol Price Chg Chg % Market Cap
ELGX 14.27 +0.19 +1.35% 830.23M
EL 54.96 -0.13 -0.24% 21.31B
EKH 50.95 +0.00 +0.00%
EJ 5.59 +0.14 +2.57% 461.01M
EIX 45.00 +0.15 +0.33% 14.66B
EIRL 20.45 +0.06 +0.29%
EIP 14.78 +0.01 +0.07%
EFII 15.44 -0.12 -0.77% 709.62M
EFG 51.82 -0.13 -0.25%
EFC 21.41 +0.11 +0.52% 353.05M
You must be signed in to use watchlists.
Sign In or Register
Create Watchlist from Stock Quotes
Close